Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment

Psychiatry Research

Volumn 188, Issue 2, 2011, Pages 197-202

  Cai, Hua Lin ^a,b   Fang, Ping Fei ^a   Li, Huan De ^a   Zhang, Xiang Hui ^a   Hu, Li ^a   Yang, Wen ^c   Ye, Hai Sen ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Department of Psychiatry   (China)

Author keywords

Monoamine metabolites; Plasma; Risperidone; Schizophrenia

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ALPRAZOLAM; DOPAMINE; HOMOVANILLIC ACID; MONOAMINE; NORADRENALIN; RISPERIDONE; SEROTONIN; TRIHEXYPHENIDYL; VANILMANDELIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; FEMALE; HUMAN; MALE; MENTAL DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; SCHIZOPHRENIA; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

3,4-DIHYDROXYPHENYLACETIC ACID; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BIOGENIC MONOAMINES; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NORDEFRIN; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 79958258122     PISSN: 01651781     EISSN: 01651781     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.11.003     Document Type: Article

References (53)

1. Alfredsson G., Wiesel F.A. Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. Psychopharmacology 1990, 101:324-331.
2. American Psychiatry Association Diagnostic and statistical manual of mental disorder, fourth ed., text revision (DSM-IV-TR) 2000, American Psychiatric Association, Washington, DC.
3. Breier A., Buchanan R.W., Waltrip R.W., Listwak S., Holmes C., Goldstein D.S. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology 1994, 10:1-7.
4. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Research 1995, 14:187-202.
5. Brown A.S., Gewirtz G., Harkavy-Friedman J., Cooper T., Brebion G., Amador X.F., Malaspina D., Gorman J.M. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology 1997, 17:317-325.
6. Cai H.-L., Zhu R.-H., Li H.-D. Determination of dansylated monoamine and amino acid neurotransmitters and their metabolites in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. Analytical Biochemistry 2010, 396:103-111.
7. Carlsson A., Waters N., Holm-Waters S., Tedroff J., Nilsson M., Carlsson M.L. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annual Review of Pharmacology and Toxicology 2001, 41:237-260.
8. Carpenter W.T., Kirkpatrick B., Buchanan R.W. Schizophrenia: syndromes and diseases. Journal of Psychiatric Research 1999, 33:473-475.
9. Carpenter W.T., Murphy D.L., Wyatt R.J. Platelet monoamine oxidase activity in acute schizophrenia. The American Journal of Psychiatry 1975, 132:438-441.
10. Chen M.-L., Chen C.-H. Chronic antipsychotics treatment regulates MAOA, MAOB and COMT gene expression in rat frontal cortex. Journal of Psychiatric Research 2007, 41:57-62.
11. Dao-Castellana M.H., Paillere-Martinot M.L., Hantraye P., Attar-Levy D., Remy P., Crouzel C., Artiges E., Féline A., Syrota A., Martinot J.L. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophrenia Research 1997, 23:167-174.
12. Davidson M., Kahn R.S., Powchik P., Warne P., Losonczy M.F., Kaminsky R., Apter S., Jaff S., Davis K.L. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Archives of General Psychiatry 1991, 48:73-76.
13. Dursun S.M., Szemis A., Andrews H., Whitaker P., Reveley M.A. Effects of clozapine and typical antipsychotic drugs on plasma 5-HT turnover and impulsivity in patients with schizophrenia: a cross-sectional study. Journal of Psychiatry & Neuroscience 2000, 25:347-352.
14. Eldrup E. Significance and origin of DOPA, DOPAC, and dopamine-sulphate in plasma, tissues and cerebrospinal fluid. Danish Medical Bulletin 2004, 51:34-62.
15. Elman I., Goldstein D.S., Green A.I., Eisenhofer G., Folio C.J., Holmes C.S., Pickar D., Breier A. Effects of risperidone on the periphreal noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo. Neuropsychopharmacology 2002, 27:293-300.
16. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). Biometrics Research 2002, New York State Psychiatric Institute, New York.
17. Frankenhaeuser M., Lundberg U., Rauste von Wright M., von Wright J., Sedvall G. Urinary monoamine metabolites as indices of mental stress in healthy males and females. Pharmacology, Biochemistry and Behavior 1986, 24:1521-1525.
18. Galinowski A., Poirier M.F., Aymard N., Leyris A., Beauverie P., Bourdel M.C., Loo H. Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol. Acta Psychiatrica Scandinavica 1998, 97:458-466.
19. Geyer M.A., Vollenweider F.X. Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences 2008, 29:445-453.
20. Goldstein D.S., Eisenhofer G., Kopin I.J. Sources and significance of plasma levels of catechols and their metabolites in humans. The Journal of Pharmacology and Experimental Therapeutics 2003, 305:800-811.
21. Hietala J., Syvalahti E., Vilkman H., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamäki M., Eronen E., Ruotsalainen U., Salokangas R.K. Depressive symptoms and presynaptic dopamine function in neuroleptic-naïve schizophrenia. Schizophrenia Research 1999, 35:41-50.
22. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 2001, 76:1521-1531.
23. Issa F., Gerhardt G.A., Bartko J.J., Suddath R.L., Lynch M., Gamache P.H., Freedman R., Wyatt R.J., Kirch D.G. A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/ unmedicated pairs analyses. Psychiatry Research 1994, 52:237-249.
24. Joyce J.N. The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology 1993, 112:S16-S34.
25. Kaminski R., Powchick P., Warne P.A., Goldstein M., McQueeney R.T., Davidson M. Measurement of plasma homovanillic acid concentrations in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1990, 14:271-287.
26. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
27. Kim Y.-K., Kim L., Lee M.-S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophrenia Research 2000, 44:165-175.
28. Konicki P.E., Owen R.R., Litman R.E., Pickar D. The acute effects of central-and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients. Life Sciences 1991, 48:1411-1416.
29. Maas J.W., Contreras S.A., Miller A.L., Berman N., Bowden C.L., Javors M.A., et al. Studies of catecholamine metabolism in schizophrenia/psychosis-I. Neuropsychopharmacology 1993, 8:97-109.
30. Markianos M., Botsis A., Arvanitis Y. Biogenic amine metabolites in plasma of drug-naive schizophrenic patients: associations with symptomatology. Biological Psychiatry 1992, 32:288-292.
31. Moncrieff J. A critique of the dopamine hypothesis of schizophrenia and psychosis. Harvard Review of Psychiatry 2009, 17:215-225.
32. Moore H., West A.R., Grace A.A. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biological Psychiatry 1999, 46:40-55.
33. Mück-Seler D., Pivac N., Mustapic M., Crncevic Z., Jakovljevic M., Sagud M. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Research 2004, 127:217-226.
34. Nagamoto H.T., Adler L.E., McRae K.A., Huettl P., Cawthra E., Gerhardt G., Hea R., Griffith J. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology 1999, 39:10-17.
35. Neff N.H., Costa E. Application of steady-state kinetics to the study of catecholamine turnover after monoamine oxidase inhibition or resperpine administration. Journal of Pharmacological and Experimental Therapeutics 1968, 160:40-47.
36. Nibuya M., Kanba S., Sekiya U., Suzuki E., Matsuo Y., Kinoshita N., Shintani F., Yagi G., Asai M. Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biological Psychiatry 1995, 38:50-56.
37. Oades R.D., Klimke A., Henning U., Rao M.L. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia. Human Psychopharmacology 2002, 17:15-27.
38. Oades R.D., Ropcke B., Henning U., Klimke A. Neuropsychological measures of attention and memory function in schizophrenia: relationships with symptom dimensions and serum monoamine activity. Behavioral and Brain Functions 2005, 1:14-30.
39. Pickar D. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: correlation with psychosis and response to neuroleptic treatment. Archives of General Psychiatry 1986, 43:669-676.
40. Pickar D., Breier A., Hsiao J.K., Doran A.R., Wolkowitz O.M., Pato C.N., et al. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis: implications for regional brain dysfunction in schizophrenia. Archives of General Psychiatry 1990, 47:641-648.
41. See R.E., Fido A.A., Maurice M., Ibrahim M.M., Salama G. Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biological Psychiatry 1999, 45:1653-1656.
42. Sharma R.P., Javaid J.I., Davis J.M., Janicak P.G. Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period. Biological Psychiatry 1998, 44:488-492.
43. Stathis P., Antoniou K., Papadopoulou-Daifotis Z., Rimikis M.N., Varonos D. Risperidone: a novel antipsychotic with many "atypical" properties?. Psychopharmacology 1996, 127:181-186.
44. Thibaut F., Ribeyre J.-M., Dourmap N., Ménard J.-F., Dollfus S., Petit M. Plasma 3-Methoxy-4-Hydroxyphenylglycol and Homovanillic Acid Measurements in Deficit and Nondeficit Forms of Schizophrenia. Biological Psychiatry 1998, 43:24-30.
45. Van der Heijden F., Tuinier S., Fekkes D., Sijben A.E.S., Kahn R.S., Verhoeven W.M.A. Atypical antipsychotics and the relevance of glutamate and serotonin. European Neuropsychopharmacology 2004, 14:259-265.
46. van Kammen D.P., Kelley M. Dopamine and norepinephrine activity in schizophrenia: An intergrative perspective. Schizophrenia Research 1991, 4:173-191.
47. Wise C., Stein L. Dopamine-β-hydroxylase deficiency in the brains of schizophrenia patients. Science 1973, 181:344-347.
48. Wyatt R.J., Potkin S.G., Bridge T.P., Phelps B.H., Wise C.D. Monoamine oxidase in schizophrenia: an overview. Schizophrenia Bulletin 1980, 6:199-206.
49. Yamamoto K., Hornykiewicz O. Proposal for a noradrenaline hypothesis of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004, 28:913-922.
50. Yoshimura R., Nakamura J., Ueda N., Terao T. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement. International Clinical Psychopharmacology 2000, 15:175-180.
51. Yoshimura R., Hori H., Sugita A., Ueda N., Kakihara S., Umene W., Nakano Y., Shinkai K., Mitoma M., Ohta M., Shinkai T., Nakamura J. Treatment with risperidone for 4weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:1072-1077.
52. Zhang Z.-J., Peet M., Ramchand C.N., Shah S., Reynolds G.P. Plasma homovanillic acid in untreated schizophrenia-relationship with symptomatology and sex. Journal of Psychiatric Research 2001, 35:23-28.
53. Zumárraga M., Dávila R., Basterreche N., Arrue A., Goienetxea B., Zamalloa M.I., Erkoreka L., Bustamante S., Inchausti L., González-Torres M.A., Guimón J. Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochemistry International 2010, 56:774-779.